<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04069442</url>
  </required_header>
  <id_info>
    <org_study_id>38RC19.100</org_study_id>
    <secondary_id>2019-A00959-48</secondary_id>
    <nct_id>NCT04069442</nct_id>
  </id_info>
  <brief_title>cDC1 Prognostic and Predictive Role in Non-Small-Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors</brief_title>
  <acronym>LUNG-PREDICT</acronym>
  <official_title>cDC1 Prognostic and Predictive Role in Non-Small-Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The response rate of immune checkpoint inhibitors remains relatively low and the&#xD;
      identification of the new predictive biomarkers is necessary. The rare population of cDC1 is&#xD;
      very interesting, as its mouse counterparts is essential for the cross presentation of&#xD;
      tumor-associated antigens, tumor immunity and response to immunotherapies. Their role in&#xD;
      humans has not been studied. This proposal aims to study the prognostic role of cDC1 in a&#xD;
      cohort of patients with advanced NSCLC, possibly demonstrating their positive predictive&#xD;
      value of immune checkpoint inhibitors response.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multicenter study aiming to collect patient's clinical data retrospectively and their&#xD;
      histological samples prospectively.&#xD;
&#xD;
      The cohort will include:&#xD;
&#xD;
        -  30 patients PD-L1 &gt; 50% treated with pembrolizumab in first line and having a&#xD;
           progression free survival ≥ 3 months&#xD;
&#xD;
        -  30 patients PD-L1 &gt; 50% treated with pembrolizumab in first line and having a&#xD;
           progression free survival &lt; 3 months&#xD;
&#xD;
        -  30 patients PD-L1 &lt; 50% treated with cisplatin-based chemotherapy in first line&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    access to human body samples by another existing cohort&#xD;
  </why_stopped>
  <start_date type="Anticipated">June 2020</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>1 year</time_frame>
    <description>To validate the cDC1 infiltration as predictive biomarker of pembrolizumab response</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>1 year</time_frame>
    <description>To compare the overall response rate (ORR) of cDC1-positive patients to cDC1 negative ones within those treated with pembrolizumab and on the entire cohort</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure (TTF)</measure>
    <time_frame>1 year</time_frame>
    <description>To compare the time of treatment failure (TTF) on CDC1-positive patients to negatives ones within those treated with pembrolizumaband on the entire cohort</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>1 year</time_frame>
    <description>To compare the overall survival (OS) of cDC1-positives patients to negatives ones within those treated with pembrolozumab and on the entire cohort</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">0</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>cDC-1 positive</arm_group_label>
    <description>cDC-1 positive patients according to RNAseq and in situ analysis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cDC-1 negative</arm_group_label>
    <description>cDC-1 negative patients according to RNAseq and in situ analysis</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>This is a non-interventional study</intervention_name>
    <description>This is a non-interventional study</description>
    <arm_group_label>cDC-1 negative</arm_group_label>
    <arm_group_label>cDC-1 positive</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Retrospective cohort of pembrolizumab or cisplatin-based chemiotherapy treated patients&#xD;
        performing these regimens in first-line according to their PD-L1 score&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  NSCLC diagnosis&#xD;
&#xD;
          -  Advanced disease (Stage III-IV) according to the TNM 7th/8th classification&#xD;
&#xD;
          -  Patients have to have performed pembrolizumab in first line if PD-L1 ≥ 50% or&#xD;
             cisplastin-based chemotherapy if PD-L1 &lt; 50%&#xD;
&#xD;
          -  FFPE material available from diagnostic sample&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elisa GOBBINI</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Grenoble Alpes</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Grenoble-Alpes</name>
      <address>
        <city>Grenoble</city>
        <state>Isère</state>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>August 12, 2019</study_first_submitted>
  <study_first_submitted_qc>August 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2019</study_first_posted>
  <last_update_submitted>March 26, 2021</last_update_submitted>
  <last_update_submitted_qc>March 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

